Recent advances in antiretroviral drugs

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 1, 2011, Pages 31-46

  Ghosh, Raktim Kumar ^a   Ghosh, Samhati Mondal ^b   Chawla, Shalini ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

CCR5 antagonist; Integrase inhibitor; Maturaton inhibitor; New antiretroviral drugs; New NRTI; New PI; QUAD pill

Indexed keywords

AMDOXOVIR; ANTIRETROVIRUS AGENT; APLAVIROC; APRICITABINE; BEVIRIMAT; CD4 IMMUNOGLOBULIN G2; COBICISTAT; DARUNAVIR; EFAVIRENZ; ELVITEGRAVIR; ELVUCITABINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FS 0101; GS 9350; GSK 1349572; IBALIZUMAB; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; PLACEBO; PRO 140; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SIFUVIRTIDE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; OUTCOME ASSESSMENT; QUALITY OF LIFE; RASH; REVIEW; SINGLE DRUG DOSE; TREATMENT INDICATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HIV; HUMANS;

EID: 78650494144     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.509345     Document Type: Review

References (81)

1. UNAIDS. AIDS epidemic update [online]. Available from: http://data. unaids.org/pub/EPISlides/2007/ 2007-epiupdate-en.pdf [Cited on 12 November 2009]
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus (HIV) infection. N Engl J Med 1998;338:853-60
3. Lundgren JD, Pedersen C, Clumeck N, et al. Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group. BMJ 1994;308:1068-73
4. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9
5. Mocroft A, Velia S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Euro SIDA Study Group. Lancet 1998;352:1725-30
6. Sun J, Ma L, Yu X, et al. Replication and drug resistant mutation of HIV-1 subtype B (Thailand B) variants isolated from HAART treatment individuals in China. Virol J 2009;6:201
7. Corona A, Raimondi F. Caring for HIV-infected patients in the ICU in the highly active antiretroviral therapy era. Caries Curr HIV Res 2009;7:569-79
8. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http://www. aidsinfo.nih.gov/ Guidelines/ GuidelineDetail.aspx? MenuItem= Guidelines&Search=Off& GuidelineID=7. Published 3 November 2008. [Accessed 7 November 2009]
9. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004;18:1393-401
10. Turner D, Wainberg MA. HIV transmission and primary drug resistance. AIDS Rev 2006;8:17-23
11. Tozzi V, Zaccarelli M, Bonfigli S, et al. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther 2006;11:553-60
12. Truong HM, Grant RM, McFarland W, et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 2006;20:2193-7
13. Drosopoulos WC, Rezende LF, Wainberg MA, et al. Virtues of being faithful: can we limit the genetic variation in human immunodeficiency virus? J Mol Med 1998;76:604-12
14. Keulen W, Nijhuis M, Schuurman R, et al. Reverse transcriptase fidelity and HIV-1 variation. Science 1997;275:229-31
15. Spira S, Wainberg MA, Loemba H, et al. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003;51:229-40
16. Bhattacharya S, Osman H. Novel targets for anti-retroviral therapy. J Infect 2009;59:377-86
17. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001;70:777-810
18. Latinovic O, Kuruppu J, Davis C, et al. Pharmacotherapy of HIV-1 infection: focus on CCR5 antagonist maraviroc. Clin Med Ther 2009;1:1497-510
19. Pierson TC, Doms RW. HIV-1 entry and its inhibition. Curr Top Microbiol Immunol 2003;281:1-27
20. Hobaika Z, Zargarian L, Maroun RG, et al. HIV-1 integrase and virus and cell DNAs: complex formation and perturbation by inhibitors of integration. Neurochem Res 2010;35:888-93
21. McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing in a new era of antiretroviral therapy. Antiviral Res 2010;85:101-18
22. Verheyen J, Verhofstede C, Knops E, et al. High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. AIDS 2010;24(5):669-7
23. Maagaard A, Kvale D. Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity. Scand J Infect Dis 2009;41:808-17
24. Balzarini J, Camarasa MJ, Perez-Perez MJ, et al. Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV. J Virol 2001;75:5772-7
25. Cases-Gonzalez CE, Franco S, Martinez MA, Menendez-Arias L. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine. J Mol Biol 2007;365:298-309
26. Li J, Li L, Li HP, et al. Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations. Chin Med J (Engl) 2009;122:1081-6
27. Wirden M, Lambert-Niclot S, Marcelin AG, et al. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients. AIDS 2009;23:95-9
28. Narayanasamy J, Pullagurla MR, Sharon A, et al. Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)- 1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D- (2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs. Antiviral Res 2007;75:198-209
29. Gripshover BM, Ribaudo H, Santana J, et al. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther 2006;11:619-23
30. Colucci P, Pottage JC, Robison H, et al. Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers. Antimicrob Agents Chemother 2009;53:646-50
31. Hurwitz SJ, Otto MJ, Schinazi RF. Comparative pharmacokinetics of Racivir, (+/-)-beta-2,3-dideoxy-5- fluoro-3-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans. Antivir Chem Chemother 2005;16:117-27
32. Cahn P, Wainberg MA. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine. J Antimicrob Chemother 2010;65:213-17
33. Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnudeoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999-5008
34. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001;65:445-8
35. Schiller DS, Youssef-Bessler M. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin Ther 2009;31:692-704
36. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38
37. Garvey L, Winston A. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs 2009;18:1035-41
38. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010;54:718-27
39. Adams J, Patel N, Mankaryous N, et al. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother 2010;44:157-65
40. Djedaini M, Peraldi P, Drici MD, et al. Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem Biophys Res Commun 2009;386:96-100
41. Caron M, Vigouroux C, Bastard JP, Capeau J. Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: alteration of the PPARgamma-dependent pathways. PPAR Res 2009;2009:507141
42. Uglietti A, Novati S, Gulminetti R, Maserati R. Correlations between atazanavir C (trough) and hyperbilirubinemia: a case report. J Med Case Rep 2009;3:9307
43. Tenore SB, Ferreira PR. The place of protease inhibitors in antiretroviral treatment. Braz J Infect Dis. 2009;13:371-4
44. Raffi F, Battegay M, Rusconi S, et al. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007;21:1977-80
45. Arasteh K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 2009;14:859-64
46. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010;24:223-30
47. Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev 2008;10:131-42
48. Estrada V, Fuster M. Darunavir in treatment-naive patients. The ARTEMIS study. Enferm Infecc Microbiol Clin 2008;26(Suppl 10):10-3
49. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients. AIDS Alert 2009;24:106-7
50. Stellbrink HJ. Raltegravir in the management of HIV-infected patients. Drug Des Dev Ther 2009;2:281-8
51. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806
52. Shimura K, Kodama EN. Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother 2009;20:79-85
53. Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple non overlapping genetic pathways. J Virol 2009;83:11440-6
54. Vandeckerckhove L. GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection. Curr Opin Investig Drugs 2010;11:203-12
55. Ray S, Fatima Z, Saxena A. Drugs for AIDS. Mini Rev Med Chem 2010;10:147-61
56. Fletcher CV. Enfuvirtide, a new drug for HIV infection. Lancet 2003;361:1577-8
57. Lalezari JP, Henry K, OHearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85
58. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95
59. He Y, Xiao Y, Song H, et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008;283:11126-34
60. Pan C, Lu H, Qi Z, Jiang S. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors. AIDS 2009;23:639-41
61. Covens K, Megens S, Dekeersmaeker N, et al. The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide. Antiviral Res 2010;86(3):253-60
62. Carter NJ, Keating GM. Maraviroc. Drugs 2007;67:2277-88
63. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010;201:803-13
64. Fadel H, Temesgen Z. Maraviroc. Drugs Today (Barc) 2007;43:749-58
65. Kummerle T, Lehmann C, Hartmann P, et al. Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection. Expert Opin Investig Drugs 2009;18:1773-85
66. Gathe J, Diaz R, Fatkenheuer G, et al. Phase 3 Trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone [abstract 54LB]. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco. 16 - 19 February 2010
67. Saracino A, Monno L, Cibelli DC, et al. Co-receptor switch during HAART is independent of virological success. J Med Virol 2009;81:2036-44
68. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006;80:4909-20
69. Jacobson JM, Thompson MA, Lalezari JP, et al. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis 2010;201:1481-7
70. Jacobson JM, Israel RJ, Lowy I, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004;48(2):423-9
71. Moyle G, DeJesus E, Boffito M, et al. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis 2009;48:798-805
72. Alexander L, Zhang S, McAuliffe B, et al. Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors. Antimicrob Agents Chemother 2009;53:4726-32
73. Bodart V, Anastassov V, Darkes MC, et al. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. Biochem Pharmacol 2009;78:993-1000
74. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004;189:286-91
75. Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009;53:450-7
76. Adamson CS, Sakalian M, Salzwedel K, Freed EO. Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat. Retrovirology 2010;7:36
77. Wainberg MA, Albert J. Can the further clinical development of bevirimat be justified? AIDS 2010;24:773-4
78. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010;87:322-9
79. UPDATE 2-Gilead Quad HIV pill succeeds in midstage study [Updated 17 Februrary 2010] http://www.reuters.com/article/idUSN1712461120100217
80. Christ F, Voet A, Marchand A, et al. First-in-class Inhibitors of LEDGF/p75-integrase Interaction and HIV replication [abstract 49]. 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010). San Francisco. 16 - 19 February 2010
81. Titolo S, Mercie J-F, Wardrop E, et al. Discovery of potent HIV-1 capsid assembly inhibitors [abstract 50]. 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010). San Francisco. 16 - 19 February 2010